Collegium Pharmaceutical Inc Stock Price, News & Analysis

Collegium Pharmaceutical reported strong Q3 2024 financial results with record net revenue of $159.3 million, up 17% year-over-year. The growth was driven by record revenues from Belbuca ($53.2M) and Xtampza ER ($49.5M). The company achieved GAAP net income of $9.3 million and record adjusted EBITDA of $105.1 million, up 18% year-over-year. A significant development was the acquisition of Ironshore Therapeutics, expanding into neurology with Jornay PM, which is expected to generate over $100 million in pro forma net revenue in 2024. The company reaffirmed its 2024 guidance with projected product revenues of $620-635 million.

Collegium Pharmaceutical (COLL) has appointed Vikram Karnani as President and CEO, effective November 12, 2024. Karnani brings over 15 years of life sciences leadership experience, notably from Horizon Therapeutics where he helped grow annual net product sales from $300 million to nearly $4 billion. He succeeds interim CEO Michael Heffernan, who will remain Board Chairman.

The appointment comes as Collegium's pain portfolio achieves record revenue, with Jornay PM positioned as the lead growth driver. Karnani most recently served as Executive VP and President of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, following its acquisition of Horizon in 2023.

Collegium Pharmaceutical has completed the acquisition of Ironshore Therapeutics, adding Jornay PM to its portfolio and establishing a presence in the ADHD market. The deal, valued at $525 million in cash, is expected to be immediately accretive to Collegium's financials. Key highlights include:

1. Jornay PM's net revenue is projected to exceed $100 million in 2024.
2. Updated 2024 guidance: Product Revenues, Net of $620.0-$635.0 million.
3. Adjusted EBITDA expected to be $395.0-$405.0 million.
4. The acquisition was funded by $200 million cash and a $325 million term loan.

This strategic move aligns with Collegium's mission to build a diversified specialty pharmaceutical company, broadening its portfolio beyond pain management.

Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. The company's management will engage in a fireside chat on Monday, September 9, 2024, at 12:30 p.m. ET.

As a leading diversified specialty pharmaceutical company, Collegium is dedicated to improving the lives of people with serious medical conditions. The fireside chat will be webcast live and can be accessed through the Investors section of Collegium's website. A replay of the webcast will remain available on the company's website for 90 days following the presentation, providing investors and interested parties with extended access to the discussion.

Collegium Pharmaceutical (Nasdaq: COLL) announced eight poster presentations at PAINWeek Conference 2024, showcasing data on its diversified pain portfolio. The posters, available from September 4-6, 2024, cover topics such as healthcare costs, treatment characteristics, safety, and nonmedical use of various pain medications including Belbuca®, Xtampza® ER, and Nucynta®.

The presentations highlight real-world data and clinical insights on Collegium's pain management products, demonstrating their impact on patient care and population health. The company emphasizes its commitment to responsible pain management and advancing its mission to improve the lives of people with serious medical conditions.

Collegium Pharmaceutical (COLL) reported strong Q2 2024 financial results, with net revenue of $145.3 million, up 7% year-over-year. Belbuca achieved record revenue of $52.2 million, a 21% increase. GAAP net income rose 51% to $19.6 million, while adjusted EBITDA grew 12% to $96.0 million. The company reaffirmed its full-year 2024 guidance and is on track to close the acquisition of Ironshore Therapeutics in Q3, adding Jornay PM to its portfolio and expanding into the ADHD market. Collegium also secured a new $646 million term loan, reducing its cost of capital by 300 basis points.

Collegium Pharmaceutical (Nasdaq: COLL) has announced a definitive agreement to acquire Ironshore Therapeutics for $525 million in cash, with a potential additional $25 million commercial milestone payment. This acquisition will expand Collegium's portfolio into neurology, specifically the ADHD market, through Ironshore's product Jornay PM. Key highlights include:

- Jornay PM's H1'24 prescriptions grew 32% year-over-year
- The transaction is expected to be immediately accretive to adjusted EBITDA
- Acquisition funded by cash on hand and new five-year financing
- Collegium estimates Q2'24 Pain Portfolio Net Revenue of $145 million, up 7% year-over-year
- The deal is expected to close in Q3 2024, subject to regulatory approvals

This strategic move aligns with Collegium's mission to build a diversified specialty pharmaceutical company, leveraging its commercial capabilities in a new market.

Collegium Pharmaceutical (Nasdaq: COLL), a diversified specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET following the release. Investors can access the call by dialing (877) 407-8037 (U.S.) or (201) 689-8037 (International) and referencing the "Collegium Pharmaceutical Q2 2024 Earnings Call." An audio webcast will be available on the company's website, with a replay accessible approximately two hours after the event.

Collegium Pharmaceutical has announced that the FDA has granted a six-month pediatric exclusivity extension for its Nucynta Franchise. This extension extends Nucynta's exclusivity to January 3, 2027, and Nucynta ER's exclusivity to December 27, 2025. The FDA had previously granted New Patient Population exclusivity for Nucynta in pediatrics, extending it until July 3, 2026. This extension is seen as a value enhancement for the Nucynta franchise, which is used for managing severe acute and persistent pain in both adults and pediatric patients. Collegium's Chief Medical Officer, Thomas Smith, highlighted the significance of this development for the company's near-term outlook and commitment to supporting patients with serious medical conditions.